Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases, and TNF-α (tumor necrosis factor) is a pro-inflammatory cytokine that plays a critical role in the pathogenesis of these conditions. Adalimumab is an anti-TNF-α drug widely used for the treatment of both psoriasis and PsA. Controlled clinical trials demonstrated that adalimumab is characterized by a high degree of clinical response. The aim of this review is to report the safety, efficacy, and recent findings in the treatment of psoriasis and PsA with adalimumab. Areas covered: This article reviews the results of Phase II, III, controlled, and observational clinical studies on adalimumab in the treatment of psoriasis and PsA. A systematic search was conducted using the Pubmed Medline database for primary articles. Expert opinion: Treatment of psoriasis and PsA represents a therapeutic challenge for dermatologists and rheumatologists. The efficacy, tolerability, and safety profiles suggest adalimumab as a suitable anti-psoriatic drug in the long-term treatment of psoriasis and PsA. Management of long-term treatment, loss of efficacy, and comorbidities has been described. © Informa UK, Ltd.

Saraceno, R., Bavetta, M., Zangrilli, A., Chiricozzi, A., Potenza, C., Chimenti, S., et al. (2013). Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(9), 1325-1334 [10.1517/14712598.2013.820701].

Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis

SARACENO, ROSITA;ZANGRILLI, ARIANNA;CHIRICOZZI, ANDREA;CHIMENTI, SERGIO;CHIMENTI, MARIA SOLE
2013

Abstract

Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases, and TNF-α (tumor necrosis factor) is a pro-inflammatory cytokine that plays a critical role in the pathogenesis of these conditions. Adalimumab is an anti-TNF-α drug widely used for the treatment of both psoriasis and PsA. Controlled clinical trials demonstrated that adalimumab is characterized by a high degree of clinical response. The aim of this review is to report the safety, efficacy, and recent findings in the treatment of psoriasis and PsA with adalimumab. Areas covered: This article reviews the results of Phase II, III, controlled, and observational clinical studies on adalimumab in the treatment of psoriasis and PsA. A systematic search was conducted using the Pubmed Medline database for primary articles. Expert opinion: Treatment of psoriasis and PsA represents a therapeutic challenge for dermatologists and rheumatologists. The efficacy, tolerability, and safety profiles suggest adalimumab as a suitable anti-psoriatic drug in the long-term treatment of psoriasis and PsA. Management of long-term treatment, loss of efficacy, and comorbidities has been described. © Informa UK, Ltd.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/16 - Reumatologia
English
Adalimumab; long-term treatment; Plaque-type psoriasis; Psoriatic arthritis; TNF-α; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Clinical Trials as Topic; Humans; Psoriasis; Quality of Life; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science
Saraceno, R., Bavetta, M., Zangrilli, A., Chiricozzi, A., Potenza, C., Chimenti, S., et al. (2013). Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(9), 1325-1334 [10.1517/14712598.2013.820701].
Saraceno, R; Bavetta, M; Zangrilli, A; Chiricozzi, A; Potenza, C; Chimenti, S; Chimenti, Ms
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/119603
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact